![]() |
市場調查報告書
商品編碼
1519340
2024-2032 年按刺激類型、設備類型、應用、最終用戶和地區分類的神經刺激設備市場報告Neurostimulation Devices Market Report by Stimulation Type, Device Type, Application, End-User, and Region 2024-2032 |
IMARC Group年,全球神經刺激設備市場規模達87億美元。人口老化的加劇、醫療保健支出的增加、非侵入性或微創神經刺激技術的發展以及政府和私人健康保險公司改進的報銷政策是推動市場的一些主要因素。
神經刺激設備是先進的醫療技術,旨在調節和影響人體內的神經活動。這些設備透過向神經系統的特定區域傳遞電或磁脈衝來發揮作用,旨在緩解各種神經系統疾病和慢性疾病。它們提供了一種有前途的非侵入性或微創治療方法,提高了患者的生活品質,並有可能為治療各種神經系統疾病開闢新途徑。神經刺激裝置的兩種主要類型是深部腦部刺激和脊髓刺激。 DBS 涉及將電極植入目標大腦區域,以調節異常神經訊號並治療帕金森氏症、特發性震顫和肌張力失調等疾病。
日益成長的老齡化人口正在推動全球市場的發展。隨著老年人口的成長,對治療這些疾病的神經刺激設備的需求可能會增加。此外,非侵入性或微創神經刺激技術的發展擴大了潛在的患者群體,因為與傳統外科手術相比,這些選擇通常可以降低風險並縮短恢復時間。此外,一些地區政府和私人醫療保險公司改善了報銷政策,使患者更容易獲得神經刺激治療,從而鼓勵了市場成長。此外,正在進行的研究和臨床試驗為神經刺激裝置的安全性和有效性提供了更多證據。這些研究的正面結果增強了醫療專業人員和患者對該技術的信心。此外,不斷成長的醫療保健支出正在支持市場解決方案的成長,因為神經刺激設備為管理慢性病提供了一種經濟有效的方法,這推動了它們的採用。
神經系統疾病的盛行率不斷增加
帕金森氏症、癲癇、慢性疼痛和憂鬱症等神經系統疾病影響著全世界數百萬人,導致沉重的醫療負擔。神經刺激裝置為傳統治療難治或出現嚴重副作用的患者提供了一個有前景的解決方案。深部腦部刺激(DBS)在治療帕金森氏症等運動障礙方面已顯示出顯著的功效,從而增加了對這些設備的需求。此外,慢性疼痛的發生率不斷上升,特別是由於人口老化和久坐的生活方式,刺激了對脊髓刺激(SCS)設備的需求,以在不嚴重依賴藥物的情況下緩解疼痛。隨著政府和醫療機構優先考慮改善患者治療效果並尋求創新解決方案,對神經刺激設備的需求預計將穩定成長。
神經刺激技術的不斷進步
持續的研究和開發努力創造了更複雜、更有針對性的神經刺激設備。創新包括更小、更精確的電極、延長的電池壽命以及整合閉迴路系統,該系統可以根據患者的即時需求自動調整刺激參數。這些進步可提高治療效果、減少副作用並提高患者舒適度。此外,植入神經刺激裝置的微創手術的發展已將其適用性擴大到更廣泛的患者群體,使治療更容易獲得,對患者和醫療保健提供者都更有吸引力。隨著技術的不斷發展,神經刺激設備可能會變得更有效率和更具適應性,從而進一步推動其採用和市場滲透。
對神經調節療法的認知和接受度不斷提高
隨著越來越多的臨床證據支持神經刺激裝置在治療各種神經系統疾病的有效性,醫生也擴大向患者推薦這些療法。此外,患者倡導團體和宣傳活動在教育個人神經刺激的潛在益處方面發揮了至關重要的作用,從而提高了患者對這些治療的接受度。透過神經刺激設備顯著改善生活品質的患者的成功故事進一步促進了人們對這些療法的正面看法。隨著對神經調節的信任不斷成長,對這些設備的需求預計會增加,從而推動市場擴張。此外,醫療保健組織、研究人員和設備製造商之間的合作,以傳播意識並確保適當的使用,將有助於神經刺激設備市場的持續成長。
The global neurostimulation devices market size reached US$ 8.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.6 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032. The growing aging population coupled with the rising healthcare expenditure, development of non-invasive or minimally invasive neurostimulation technologies, and improved reimbursement policies by government and private health insurers are some of the major factors propelling the market.
Neurostimulation devices are advanced medical technologies designed to modulate and influence neural activity within the human body. These devices work by delivering electrical or magnetic impulses to specific regions of the nervous system, aiming to alleviate various neurological conditions and chronic disorders. They offer a promising non-invasive or minimally invasive therapeutic approach, enhancing the quality of life for patients and potentially opening up new avenues for treating various neurological disorders. The two primary types of neurostimulation devices are deep brain stimulation and spinal cord stimulation. DBS involves implanting electrodes into targeted brain areas to regulate abnormal neural signals and treat conditions such as Parkinson's disease, essential tremor, and dystonia.
The growing aging population is driving the global market. As the elderly population grows, the demand for neurostimulation devices to manage these conditions is likely to rise. Moreover, the development of non-invasive or minimally invasive neurostimulation technologies has expanded the potential patient pool, as these options often offer reduced risks and quicker recovery times compared to traditional surgical procedures. Besides, improved reimbursement policies by government and private health insurers in some regions have made neurostimulation treatments more accessible to patients, encouraging market growth. Also, ongoing research and clinical trials have provided additional evidence for the safety and efficacy of neurostimulation devices. Positive results from these studies have increased confidence in the technology among medical professionals and patients. Furthermore, the rising healthcare expenditure is supporting the growth of market solutions as neurostimulation devices offer a cost-effective approach to managing chronic conditions, which has driven their adoption.
Increasing Prevalence of Neurological Disorders
Neurological conditions such as Parkinson's disease, epilepsy, chronic pain, and depression affect millions of people worldwide, leading to significant healthcare burdens. Neurostimulation devices offer a promising solution for patients who are refractory to conventional treatments or experience severe side effects. Deep brain stimulation (DBS) has demonstrated remarkable efficacy in managing movement disorders, such as Parkinson's disease, thereby augmenting the demand for these devices. Additionally, the escalating incidence of chronic pain, particularly due to aging populations and sedentary lifestyles, fuels the need for spinal cord stimulation (SCS) devices to provide pain relief without relying heavily on medications. As governments and healthcare organizations prioritize improved patient outcomes and seek innovative solutions, the demand for neurostimulation devices is expected to grow steadily.
Continual Advancements in Neurostimulation Technologies
Continuous research and development efforts have led to the creation of more sophisticated and targeted neurostimulation devices. Innovations include smaller and more precise electrodes, improved battery life, and the integration of closed-loop systems that can automatically adjust stimulation parameters based on real-time patient needs. These advancements translate to enhanced treatment outcomes, reduced side effects, and increased patient comfort. Moreover, the development of minimally invasive procedures for implanting neurostimulation devices has expanded their applicability to a broader patient population, making the treatments more accessible and appealing to both patients and healthcare providers. As technology continues to evolve, neurostimulation devices will likely become even more efficient and adaptable, further impelling their adoption and market penetration.
Growing Awareness and Acceptance of Neuromodulation Therapies
As more clinical evidence supports the effectiveness of neurostimulation devices in treating various neurological disorders, medical practitioners increasingly recommend these therapies to their patients. Additionally, patient advocacy groups and awareness campaigns have played a crucial role in educating individuals about the potential benefits of neurostimulation, leading to greater patient acceptance of these treatments. The success stories of patients who have experienced significant improvements in their quality of life through neurostimulation devices have further contributed to the positive perception of these therapies. As trust in neuromodulation grows, the demand for these devices is expected to increase, fuelling the market expansion. Furthermore, collaborations between healthcare organizations, researchers, and device manufacturers to spread awareness and ensure appropriate usage will contribute to the sustained growth of the neurostimulation devices market.
IMARC Group provides an analysis of the key trends in each segment of the global neurostimulation devices market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on stimulation type, device type, application, and end-user.
Internal Stimulation
External Stimulation
The report has provided a detailed breakup and analysis of the market based on the stimulation type. This includes internal stimulation and external stimulation.
Internal stimulation devices form a significant segment within the neurostimulation market, characterized by their implantable nature. These devices are surgically placed within the body to deliver targeted electrical or magnetic stimulation directly to specific neural structures. The demand for internal stimulation devices is driven by their efficacy in managing complex neurological disorders that do not respond adequately to medications or other treatments. The ability to precisely target neural circuits while providing reversible and adjustable stimulation parameters enhances treatment outcomes, leading to improved patient quality of life.
On the other hand, external stimulation devices represent another substantial segment in the neurostimulation market, characterized by their non-invasive or minimally invasive nature. These devices are applied externally to the body's surface, delivering stimulation without the need for surgical implantation.
SCS (Spinal Cord Stimulation) Devices
DBS (Deep Brain Stimulation) Devices
SNS (Sacral Nerve Stimulation) Devices
VNS (Vagus Nerve Stimulation) Devices
GES (Gastric Electrical Stimulation) Devices
Transcutaneous Electrical Nerve Stimulation Devices
Transcranial Magnetic Stimulation Devices
Others
SCS (spinal cord stimulation) dominates the market
The report has provided a detailed breakup and analysis of the market based on the device type. This includes spinal cord stimulation (SCS) devices, deep brain stimulation (DBS) devices, sacral nerve stimulation (SNS) devices, vagus nerve stimulation (VNS) devices, gastric electrical stimulation (GES) devices, transcutaneous electrical nerve stimulation devices, transcranial magnetic stimulation devices, and other. According to the report, SCS (spinal cord stimulation) devices represented the largest segment.
SCS involves the implantation of electrodes along the spinal cord, where electrical impulses are delivered to modulate pain signals and provide relief for chronic pain conditions. The minimally invasive nature of the procedure offers numerous benefits, including shorter recovery times and reduced risks compared to invasive surgeries. Additionally, the customizable nature of SCS allows for individualized programming to target specific pain areas, tailoring treatment to meet each patient's unique needs. Moreover, continual advancements in SCS technology have led to more sophisticated devices with improved battery life, smaller implants, and enhanced programming capabilities, providing greater patient comfort and long-term sustainability. The focus on patient-centered care and shared decision-making has led to an increased emphasis on personalized pain management plans. Spinal cord stimulation, with its individualized programming capabilities, aligns well with this patient-centric approach, fueling its adoption in pain management strategies.
Pain Management
Epilepsy
Essential Tremors
Urinary and Fecal Incontinence
Depression
Dystonia
Parkinson's Disease
Others
Pain management dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes pain management, epilepsy, essential tremors, urinary and fecal incontinence, depression, dystonia, Parkinson's disease, and others. According to the report, pain management represents the largest segment.
Neurostimulation devices designed for pain management offer a promising alternative, particularly spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). These technologies work by delivering controlled electrical impulses to target nerves, modulating pain signals, and thereby reducing the perception of pain. Pain management through neurostimulation has demonstrated remarkable efficacy in various chronic pain conditions, including neuropathic pain, failed back surgery syndrome (FBSS), and complex regional pain syndrome (CRPS). Additionally, the advancements in neurostimulation technology have led to more personalized and precise pain management solutions, allowing for tailored treatment strategies based on individual patient needs.
Rehabilitation Centers
Hospitals
Medical Clinics
Others
Hospitals dominates the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes rehabilitation centers, hospitals, medical clinics, and others. According to the report, hospitals represented the largest segment.
Hospitals play a central role in the diagnosis, treatment, and management of various neurological and chronic disorders, which often require neurostimulation therapies as part of the treatment plan. Hospitals have access to multidisciplinary teams of medical professionals, including neurologists, neurosurgeons, pain specialists, and anesthesiologists, who collaborate to provide comprehensive care to patients requiring neurostimulation therapies. Additionally, they are equipped with state-of-the-art operating rooms and facilities that meet stringent regulatory standards, ensuring safe and effective implantation procedures. Furthermore, neurostimulation devices often require careful programming and adjustments to optimize treatment outcomes, and hospitals have the resources to support these ongoing patient management needs.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest neurostimulation devices market share.
The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others), Latin America (Brazil, Mexico, and Others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America has a well-established healthcare infrastructure and is at the forefront of medical research and technological advancements. The presence of leading healthcare facilities, specialized neurology centers, and renowned research institutions fosters innovation and the adoption of cutting-edge neurostimulation technologies. Moreover, the region has a high prevalence of neurological disorders and chronic pain conditions, leading to a substantial demand for neurostimulation devices for effective management and treatment. The region's aging population, coupled with a growing awareness of neurostimulation therapies among patients and healthcare providers, further fuels market growth. Additionally, favorable reimbursement policies and regulatory frameworks in North America support the widespread adoption of neurostimulation devices.
Neurostimulation device manufacturers are heavily investing in research and development to enhance their existing products and develop new, innovative technologies. This involves conducting clinical trials, exploring new applications for neurostimulation, and improving the safety and efficacy of their devices. Moreover, companies are introducing new neurostimulation devices or release upgraded versions of existing ones. These launches aim to provide patients and healthcare professionals with state-of-the-art solutions that offer better outcomes and user experiences. Furthermore, companies actively seek to expand their market presence, both geographically and in terms of applications. They may pursue regulatory approvals in different regions, explore new therapeutic areas for neurostimulation, or target specific patient populations with unmet needs. Also, collaboration with other companies, research institutions, and healthcare organizations is common in the neurostimulation devices market.
Biocontrol Medical
Boston Scientific Corporation
Cyberonics Inc.
Medtronic Inc.
Neuronetics Inc.
Neuropace Inc.
Neurosigma Inc.
Nevro Corporation
ST. Jude Medical Inc.
Synapse Biomedical Inc.
In April 2023, Synapse Biomedical Inc. received the approval for diaphragm pacing system, NeuRx DPS(R). The NeuRx DPS(R) is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy. It is intended for use in patients with stable SCI with stimulatable diaphragms, but who lack control of their diaphragms. The device is indicated to allow patients 18 years and older to breathe without the assistance of a mechanical ventilator for at least four continuous hours a day.
In March 2023, Nevro Corporation announced the Launch of Revolutionary HFX iQ(TM) Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain. It combines clinical inputs, such as pain relief and pain score, along with quality of life inputs, such as pain medication and activity level changes, to provide an individualized program setting for each patient.
In September 2022, Neuronetics Inc. launched Innovations to NeuroStar(R) Advanced Therapy's Proprietary TrakStar(R) Platform. The TrakStar upgrades include a simplified interface to quickly sort and prioritize potential patients with ease. It also streamlines the patient journey by bridging our proprietary PHQ-10 platform with our HIPAA-compliant TrakStar patient data management system making it easier to identify new patients and those needing re-treatment.